Compare Norfolk Southern Corporation (NSC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Norfolk Southern Corporation trades at $317.24 (market cap $70.35B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Norfolk Southern Corporation and Regeneron Pharmaceuticals Inc are close in size by market cap, and Norfolk Southern Corporation pays the higher dividend (1.72%). Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| NSC | REGN | |
|---|---|---|
Market Cap | $70.35B | $76.40B |
Volume | 825,542 | 626,381 |
Sector | Industrials | Health |
52-Week High | $352.98 | $852.03 |
52-Week Low | $278.19 | $557.73 |
Typical Hold Time | 33 Days | 107 Days |
Enterprise Value | $85.89B | $71.12B |
Dividend Yield | 1.72% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $313.20, down 0.98% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.52 exceeding expectations by 6%. Valuation metrics include P/E of 26.72 and ROE of 16.97%, while the proposed Union Pacific merger progresses through regulatory review. Cash flow trends show operational strength with $4.36B from operations in 2025.
Outlook remains constructive with 43.75% analyst buy ratings and $361.86 consensus target offering 15.5% upside. Key risks include merger approval uncertainty and fuel cost pressures. The combination creates transcontinental railroad opportunities but faces STB regulatory hurdles. Earnings on October 22, 2026 will be critical for near-term direction.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
